The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or without mixed features.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
150
Oral administration
Oral administration
Neurocrine Clinical Site
Little Rock, Arkansas, United States
RECRUITINGNeurocrine Clinical Site
Garden Grove, California, United States
RECRUITINGNeurocrine Clinical Site
Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Day 21
Time frame: Baseline, Day 21
Change From Baseline in Clinical Global Impression - Severity Scale (CGI-S) Score at Day 21
Time frame: Baseline, Day 21
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
San Diego, California, United States
Neurocrine Clinical Site
Hollywood, Florida, United States
RECRUITINGNeurocrine Clinical Site
Atlanta, Georgia, United States
RECRUITINGNeurocrine Clinical Site
Gaithersburg, Maryland, United States
RECRUITINGNeurocrine Clinical Site
Marlton, New Jersey, United States
RECRUITINGNeurocrine Clinical Site
Staten Island, New York, United States
RECRUITINGNeurocrine Clinical Site
Austin, Texas, United States
RECRUITING